MARISSA GENOVESE: Open Payments
NPI 1629805742 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,003 in 220 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $273 · 2025 $4,003
Food & beverage: $3,891Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 27 | $603 |
| Teva Pharmaceuticals USA, Inc. | 27 | $560 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $364 |
| Alkermes, Inc. | 15 | $277 |
| Janssen Pharmaceuticals, Inc | 14 | $268 |
| Axsome Therapeutics, Inc. | 15 | $266 |
| ABBVIE INC. | 22 | $255 |
| Vanda Pharmaceuticals Inc. | 9 | $218 |
| Almatica Pharma LLC | 14 | $215 |
| Bausch Health US, LLC | 10 | $211 |
Products named: INGREZZA, AUSTEDO XR, CAPLYTA, REXULTI, Auvelity, ARISTADA, FANAPT, LOREEV XR.
Industry payments across OR — which companies pay providers there.
